SEPN Stock Price, Chart, Stats & News
Septerna, Inc. Common Stock (SEPN) does not currently pay a dividend.
SEPN chart
Fundamentals
Gross margin | 100.00% |
Operating margin | -148.63% |
Pretax margin | -106.35% |
Net margin | -106.37% |
Effective tax rate | -0.02% |
ROA | -8.20% |
ROE | -12.63% |
D/E | 0.06x |
Interest coverage ratio | – |
SEPN valuation
P/E | – |
P/S | 23.33x |
P/B | 2.77x |
P/CF | 9.59x |
P/FCF | 9.77x |
P/OCF | 9.59x |
PEG | -0.82x |
EV multiple | -14.76x |
About
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.
Similar securities
Based on sector and market capitalization
